2123/5FW



## ATTORNEY DOCKET NO. 14014.0410U1 SERIAL NO. 10/517,898

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

)	
)	Art Unit: 2123
)	Examiner: Unassigned
)	Confirmation No. 5707
)	
)	
	) ) ) ) ) ) )

## INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C. Customer Number 36339

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys. In accordance with 37 C.F.R. §1.98(a)(2), copies of any cited U.S. patent or U.S. patent application publication documents are not enclosed. Copies of any cited foreign patent document and/or any non-patent publication are enclosed.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(3), in that a first Office Action on the merits of the present patent application has not yet been mailed to Applicants.



## ATTORNEY DOCKET NO. 14014.0410U1 SERIAL NO. 10/517,898

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

No fee is believed due; however, the Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Lizette M. Fernandez, Ph.D. Registration No. 46,694

NEEDLE & ROSENBERG, P.C. Customer Number 36339 (678) 420-9300 (678) 420-9301 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8
I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450,\on theldate indicated below.


Attorney Docket No.: 14014.0410U1 U.S. Application Serial No.: 10/517,898 Sheet 1 of 6

OTPE IN B

INFORMATION DISCLOSURE STATEMENT LIST

Complete if Known
Application Number 10/517,898
Filing Date 14 June 2002
First Named Inventor Warren Strober
Group Art Unit 2123
Examiner Name Unassigned


				First Named Inver	itoi	warren suc	opei
	(Use as ma	Use as many sheets as necessary)  Group Art Unit			2123		
				Examiner Name		Unassigned	
			J.S. PATEN	T DOCUMENTS			
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate
	B1	2002/0042387	04/11/02	Eyal et al.			
	B2	6,143,871	11/07/00	Bonnefoy et al.			
	B3	5,614,191	03/25/97	Puri et al.			
	B4	6,518,061	02/11/03	Puri et al.			
	B5	2004/0043921	03/04/04	Bonnefoy et al.			
			<u> </u>				
	Y-11-			ENT DOCUMENTS			
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number- Kind Code	Date	Name Translation Yes/No		s/No	
	B6	WO 00/02923	01/20/00	Nickoloff			
	B7	WO 00/02583	01/20/00	Nickoloff	0		
		1	ION-PATEN	T DOCUMENTS			•
Examiner's Initials	Cite No.	Non-Pate	nt Citations (incl	ide Author, Title, Publisher, Relevan	nt Pages, Da	ate and Place of Publi	cation)
	В8	Balk, S. P., Bleicher, P. A., and Terhorst, C. (1989). Isolation and characterization of a cDNA and gene coding for a fourth CD1 molecule. Proc Natl Acad Sci U S A 86, 252-256.					
	B9	Bendelac, A. (1995). Positive selection of mouse NK1+ T cells by CD1-expressing cortical thymocytes. J Exp Med 182, 2091-2096.			1-expressing		
	B10	Bleicher, P. A., Balk, S. P., Hagen, S. J., Blumberg, R. S., Flotte, T. J., and Terhorst, C. (1990). Expression of murine CD1 on gastrointestinal epithelium. Science 250, 679-682.					
	B11	Blumberg, R. S., Terhorst, C., Bleicher, P., McDermott, F. V., Allan, C. H., Landau, S. B., Trier, J. S., and Balk, S. P. (1991). Expression of a nonpolymorphic MHC class I-like molecule, CD1D, by human intestinal epithelial cells. J Immunol 147, 2518-2524.					
	B12	Boirivant, M., Fu murine model	of T helper	u, A., and Strober, W. cell type 2 colitis treat 88, 1929-1939.			
	B13	Bonish B, Jullien D, Dutronc Y, Huang BB, Modlin R, Spada FM, Porcelli SA, Nickoloff BJ. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol. 2000 Oct 1;165(7):4076-85.					
	B14	Brown, KD, Zurawski SM, Mosmann TR, Zurawski G. A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes <i>J. Immunol.</i> 142 (2), 679-687 (1989).			that vth factors,		
	B15	Brown, M. A., and Hural, J. (1997). Functions of IL-4 and control of its expression Crit Rev Immunol 17, 1-32.			expression.		





Complete if Known 10/517,898 Application Number **INFORMATION DISCLOSURE** 

	HON DISCLOSURE		
STATEMENT LIST		Filing Date	14 June 2002
		First Named Inventor	Warren Strober
(Use as many sheets as necessary)		Group Art Unit	2123
			Unassigned
B16	Brown, TE, Bankhurst AD, Str lymphocyte subpopulation p lmmunol. 1983 Jul;11(3):11	profiles in inflammatory boy	
B17	Camoglio L, Te Velde AA, Tig expression of interferon-gar disease. Inflamm Bowel Dis	ges AJ, Das PK, Van Deve nma and interleukin-4 in in	
B18	Ceponis, P. J., Botelho, F., Richards, C. D., and McKay, D. M. (2000). Interleukins 4 and 13 increase intestinal epithelial permeability by a phosphatidylinositol 3-kinase pathway. Lack of evidence for STAT 6 involvement. J Biol Chem 275, 29132-29137.		
B19	Chen, H., and Paul, W. E. (1997). Cultured NK1.1+ CD4+ T cells produce large amounts of IL-4 and IFN- gamma upon activation by anti-CD3 or CD1. J Immunol 159, 2240-2249.		
B20	Cui, J., Shin, T., Kawano, T., Sato, H., Kondo, E., Toura, I., Kaneko, Y., Koseki, H., Kanno, M., and Taniguchi, M. (1997). Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278, 1623-1626.		
B21	del Mar Cabrera M, Valle J, Pajares JM, Romero I, Zomeno M, Mate J. Expression of the Kp43 (CD 94) receptor by natural killer (NK) cells in ulcerative colitis. Hepatogastroenterology. 2001 Sep-Oct;48(41):1316-20.		
B22	Desreumaux P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O, Ectors N, Cortot A, Capron M, Colombel JF. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology. 1997 Jul;113(1):118-26.		
B23	Dolganov, et al. "Coexpression correlates with their physical chromosome 5q23-31" <i>Bloo</i>	I linkage in the cytokine ge	ene cluster on human
B24	Donaldson, D. D., Whitters, M. J., Fitz, L. J., Neben, T. Y., Finnerty, H., Henderson, S. L., O'Hara, R. M., Jr., Beier, D. R., Turner, K. J., Wood, C. R., and Collins, M. (1998). The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol 161, 2317-2324.		
B25	Fiocchi C, Tubbs RR, Youngman KR. Human intestinal mucosal mononuclear cells exhibit lymphokine-activated killer cell activity. Gastroenterology. 1985 Mar;88(3):625-37.		
B26	Fiorentino, D. F., Zlotnik, A., Vieira, P., Mosmann, T. R., Howard, M., Moore, K. W., and O'Garra, A. (1991). IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146, 3444-3451.		
B27	Fort, M. M., Cheung, J., Yen, Clifford, T., Hunte, B., Lesle 13 and Th2-associated path	y, R., et al. (2001). IL-25 ir	nduces IL-4, IL-5, and IL-
B28	Fuss, I. J., Neurath, M., Boiriv Fiocchi, C., and Strober, W. lymphokine secretion profile LP cells manifest increased LP cells manifest increased	(1996). Disparate CD4+ la es in inflammatory bowel di secretion of IFN-gamma, v	amina propria (LP) sease. Crohn's disease whereas ulcerative colitis






INFORMATION DISCLOSURE STATEMENT LIST


Compl	ete if Known	
Application Number	10/517,898	
Filing Date	14 June 2002	
First Named Inventor	Warren Strober	
Group Art Unit	2123	
Examiner Name	Unassigned	

1	I LIVILIY I LIQ I			
		First Named Inventor	Warren Strober	
(Use as many sheets as necessary)		Group Art Unit	2123	
		Examiner Name	Unassigned	
B29	Ginsburg CH, Dambrauskas JT, Ault KA, Falchuk ZM. Impaired natural killer cell activity in patients with inflammatory bowel disease: evidence for a qualitative defect. Gastroenterology. 1983 Oct;85(4):846-51.			
B30	Gumperz, J. E., Roy, C., Mako Koezuka, Y., Porcelli, S. A., (2000). Murine CD1d-restric 211-221.	Cardell, S., Brenner, M. B	., and Behar, S. M.	
B31	Hayakawa, K., Lin, B. T., and subsets: a subset (Thy0) tha V beta 8 T cell receptor gen	at secretes diverse cytokin	es and overexpresses the	
B32	Inoue S, Matsumoto T, lida M Characterization of cytokine correlation with disease acti	expression in the rectal m	nucosa of ulcerative colitis:	
B33	Ishikawa, H., Hisaeda, H., Tar Nakano, Y., Zhang, M., Zha v(alpha)14 NKT cells play a against infection with Leishn	niguchi, M., Nakayama, T., ng, T., Nishitani, M., et al. crucial role in an early sta	Sakai, T., Maekawa, Y., (2000). CD4(+) ge of protective immunity	
B34	Kadivar K, Defelice ML, Marko interleukin-13 in pediatric int Pediatr Gastroenterol Nutr. 2	flammatory bowel disease		
B35	Kaneko, Y., Harada, M., Kawa Nakayama, T., and Tanigud mediated cytotoxicity by inte development of concanavali	hi, M. (2000). Augmentatio erleukin 4 in an autocrine n	on of Valpha14 NKT cell- nechanism resulting in the	
B36	Kawano, T., Cui, J., Koezuka, Nakagawa, R., Sato, H., Koi mediated activation of valph 1626-1629.	ndo, E., et al. (1997). CD1	d-restricted and TCR-	
B37	Koyasu, S. (1994). CD3+CD10 from both alpha-beta TCR+0 J Exp Med 179, 1957-1972.	CD4-CD8- and gamma-de		
B38	Kucharzik T, Lugering N, Adol immunoregulatory cytokines inflammatory bowel disease	on peripheral blood mond	ocytes from patients with	
B39	Kumar, H., Belperron, A., Barthold, S. W., and Bockenstedt, L. K. (2000). Cutting edge: CD1d deficiency impairs murine host defense against the spirochete, Borrelia burgdorferi. J Immunol 165, 4797-4801.			
B40	Lakatos L. Immunology of infla 2000;87(4):355-72.	ammatory bowel diseases.	Acta Physiol Hung.	
B41	Lantz, O., and Bendelac, A. (1 used by a unique subset of r CD4+ and CD4-8- T cells in	major histocompatibility co	mplex class I-specific	
B42	Lee, P. T., Benlagha, K., Teyto lineages of human V(alpha)			



TPE 4000

			te if Known	
INFORMATION DISCLOSURE		Application Number	10/517,898	
ST	ATEMENT LIST	Filing Date	14 June 2002	
		First Named Inventor	Warren Strober	
(Use as	many sheets as necessary)	Group Art Unit	2123	
		Examiner Name	Unassigned	
B43	Lugering N, Kucharzik T, Stei Stoll R. IL-10 synergizes wi secretion by human monoc patients with inflammatory b	th IL-4 and IL-13 in inhibiti ytes and lamina propria m	ng lysosomal enzyme ononuclear cells from	
B44	Mack DR, Beedle S, Warren Cytokine analysis in children Pediatr Res. 2002 Mar;51(3	n newly diagnosed with infl		
B45	Manzano L, Alvarez-Mon M, A Corugedo F, Durantez A. F ulcerative colitis: reversion Gut. 1992 Feb;33(2):246-52	Abreu L, Antonio Vargas J unctional impairment of na of the defective natural kill	itural killer cells in activ	
B46	Minty, A., Asselin, S., Bensus Wijdenes, J., Ferrara, P., ar interleukin-13 and interleuk differential effects on T lym	nd Caput, D. (1997). The r in-4 are distinguished by d	elated cytokines ifferential production a	
B47		Miyamoto, K., Miyake, S., and Yamamura, T. (2001). A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer		
B48	interleukin 4 but not interfer	Mizoguchi, A., Mizoguchi, E., and Bhan, A. K. (1999). The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor alpha mutant mice. Gastroenterology 116, 320-326.		
B49		Moore, K. W., O'Garra, A., de Waal Malefyt, R., Vieira, P., and Mosmann, T. R. (1993). Interleukin-10. Annu Rev Immunol 11, 165-190.		
B50	Neurath, M. F., Fuss, I., Kelsa Antibodies to interleukin 12 Exp Med 182, 1281-1290.			
B51	Park, S. H., Roark, J. H., and mouse CD1 molecules. J In		ue-specific recognition	
B52	Parronchi, P., Romagnani, P. Giannarini, L., Maggi, E., Po Type 1 T-helper cell predon patients with Crohn's disease	upilli, C., Tonelli, F., and R ninance and interleukin-12	omagnani, S. (1997). expression in the gut	
B53	·	Radford-Smith G, Jewell DP. Cytokines and inflammatory bowel disease. Baillieres Clin Gastroenterol. 1996 Mar;10(1):151-64.		
B54	Roark, J. H., Park, S. H., Jaya Bendelac, A. (1998). CD1.1 marginal zone B cells. J Imr	expression by mouse ant		
B55	Rogler G, Andus T. Cytokines Apr;22(4):382-9.	s in inflammatory bowel dis	sease. World J Surg. 1	
B56	Sartor, R. B. (1995). Current of	concepts of the etiology and streets of the etiology at the etiology and streets of the etiology at the etiology at the etiology at the etiolo		





**INFORMATION DISCLOSURE** STATEMENT LIST

**Examiner Name** 

10/517,898 **Application Number** 14 June 2002 Filing Date First Named Inventor Warren Strober Group Art Unit 2123 Unassigned

Complete if Known

(Use as many sheets as necessary)

B57	Saubermann LJ, Beck P, De Jong YP, Pitman RS, Ryan MS, Kim HS, Exley M, Snapper S, Balk SP, Hagen SJ, Kanauchi O, Motoki K, Sakai T, Terhorst C, Koezuka Y, Podolsky DK, Blumberg RS. Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology. 2000 Jul;119(1):119-28.
B58	Scheiffele, F., Fuss, I. (2002). Induction of TNBS colitis in mice, Vol 15.19, John Wiley & Sons, Inc.).
B59	Shinoda M, Haruta J, Tanimoto M, Ando T, Hosokawa T, Ina K, Kusugami K. Lamina propria mononuclear cells express and respond to interleukin-2 differently in Crohn's disease and ulcerative colitis. Intern Med. 1996 Sep;35(9):679-85.
B60	Singh B, Powrie F, Mortensen NJ. Immune therapy in inflammatory bowel disease and models of colitis. Br J Surg. 2001 Dec;88(12):1558-69.
B61	Smiley, S. T., Kaplan, M. H., and Grusby, M. J. (1997). Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells. Science 275, 977-979.
B62	Sonoda, K. H., Exley, M., Snapper, S., Balk, S. P., and Stein-Streilein, J. (1999). CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J Exp Med 190, 1215-1226.
B63	Spada, F. M., Koezuka, Y., and Porcelli, S. A. (1998). CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 188, 1529-1534.
B64	Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495-549. Epub 2001 Oct 4.
B65	Strober, S., Cheng, L., Zeng, D., Palathumpat, R., Dejbakhsh-Jones, S., Huie, P., and Sibley, R. (1996). Double negative (CD4-CD8- alpha beta+) T cells which promote tolerance induction and regulate autoimmunity. Immunol Rev 149, 217230.
B66	Takeda, K., Hayakawa, Y., Van Kaer, L., Matsuda, H., Yagita, H., and Okumura, K. (2000). Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A 97, 5498-5503.
B67	Tamura J, Jinbo T, Itoh K, Take H, Matsushima T, Murakami H, Kubota K, Tsuchiya J, Naruse T. Suppressed natural killer cell activity in ulcerative colitis. J Med. 1994;25(5):337-40.
B68	Terabe, M., Matsui, S., Noben-Trauth, N., Chen, H., Watson, C., Donaldson, D. D., Carbone, D. P., Paul, W. E., and Berzofsky, J. A. (2000). NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1, 515-520.
B69	Urban, J. F., Jr., Noben-Trauth, N., Donaldson, D. D., Madden, K. B., Morris, S. C., Collins, M., and Finkelman, F. D. (1998). IL-13, IL-4Ralpha, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity 8, 255-264.
B70	Vainer B, Nielsen OH, Hendel J, Horn T, Kirman I. Colonic expression and synthesis of interleukin 13 and interleukin 15 in inflammatory bowel disease. Cytokine: 2000 Oct;12(10):1531-6.



Attorney Docket No.: 14014.0410U1 U.S. Application Serial No.: 10/517,898 Sheet 6 of 6

			te if Known
INFORMATION DISCLOSURE STATEMENT LIST		Application Number	10/517,898
		Filing Date	14 June 2002
		First Named Inventor	Warren Strober
(Use as ma	many sheets as necessary)  Group Art Unit  2123		2123
		Examiner Name	Unassigned
B71	van Tol EA, Verspaget HW, Pena AS, Lamers CB. Normal inflammatory bowel disease mucosa conceals alterations in natural killer cell activity. Scand J Gastroenterol. 1992 Dec;27(12):999-1005.		
B72	Vezys, V., Olson, S., and Lefrancois, L. (2000). Expression of intestine-specific antigen reveals novel pathways of CD8 T cell tolerance induction. Immunity 12, 505-514.		
B73	Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., and Donaldson, D. D. (1998). Interleukin-13: central mediator of allergic asthma. Science 282, 2258-2261.		
B74	Yoshimoto, T., and Paul, W. E. (1994). CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 179, 1285-1295.		
B75	Zurawski, G., and de Vries, J. cytokine that acts on monoci 15, 19-26.		
caminer Signature:	Date Consid	dered:	
KAMINER: Initial if re	eference considered, whether or not cit	ation is in conformance with MPE	EP 609; Draw line through citati
tot in conformance and	not considered. Include copy of this for	m with next communication to a	opiicant.